Tanvex BioPharma

Tanvex BioPharma EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Tanvex BioPharma (6541.TW) as of Nov 22, 2026 is -1.39 B TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -1.36 B TWD — a change of 2.43% (lower).

EBITDA

-1.39 BTWD

YoY

2.43%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Tanvex BioPharma is 2025 -1.39 B TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Tanvex BioPharma was 2024 -1.36 B TWD. It decreases by 2.43% lower compared to the previous year.

The Tanvex BioPharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-1.94 B TWD
Jan 1, 2019
-2.25 B TWD
Jan 1, 2020
-2.08 B TWD
Jan 1, 2021
-1.49 B TWD
Jan 1, 2022
-1.58 B TWD
Jan 1, 2023
-2.10 B TWD
Jan 1, 2024
-1.36 B TWD
Jan 1, 2025
-1.39 B TWD
The Tanvex BioPharma EBITDA history
YEAREBITDAYoY
-1.39 BTWD+2.43%
-1.36 BTWD-35.45%
-2.10 BTWD+32.47%
-1.58 BTWD+6.02%
-1.49 BTWD-28.17%
-2.08 BTWD-7.60%
-2.25 BTWD+16.08%
-1.94 BTWD+39.74%
-1.39 BTWD+3.71%
-1.34 BTWD+62.38%
-824.50 MTWD+77.35%
-464.90 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tanvex BioPharma Stock analysis

What does Tanvex BioPharma do? Tanvex BioPharma, Inc. generates revenue through the development and sale of pharmaceutical products, including its pipeline of biologic and biosimilar drugs. The company focuses on clinical-stage research and development, leveraging expertise in strain and cell-line development, cell culture, and protein purification. Products such as Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), and Perjeta (TX-52) are central to its offerings, targeting specific therapeutic areas. The vertically integrated manufacturing platform enables cost-effective production of drug substances and products, supporting both biologics and biosimilars. The firm serves healthcare providers, hospitals, and pharmaceutical distributors who purchase its biologic and biosimilar drugs. These stakeholders rely on Tanvex BioPharma’s vertically integrated manufacturing capabilities to ensure supply chain efficiency and product quality. The company’s pipeline includes established drug names like Neupogen and Herceptin, which are repurposed under its internal product codes (TX-01, TX-05, etc.), allowing for strategic market positioning. Its focus on microbial and mammalian systems ensures versatility in producing diverse therapeutic solutions. Tanvex BioPharma’s revenue streams are derived from the sale of its pipeline products, including Neupogen (TX-01), Herceptin (TX-05), and others, which are developed through its integrated R&D and manufacturing processes. The company’s expertise in cell culture, process scale-up, and drug manufacturing supports the production of high-quality biopharmaceuticals. By offering a comprehensive platform for biologic and biosimilar drug development, Tanvex BioPharma caters to the growing demand for affordable and effective therapeutic options in the pharmaceutical market. Tanvex BioPharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tanvex BioPharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Tanvex BioPharma is -1.39 B TWD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Tanvex BioPharma changed from -1.36 B TWD to -1.39 B TWD, representing a 2.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Tanvex BioPharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Tanvex BioPharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Tanvex BioPharma

All Key Metrics — Tanvex BioPharma